A Sensitive in Vitro High-Throughput Screen to Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface

Gai Liu, Peter J. Nash, Britney Johnson, Colette Pietzsch, Ma Xenia G. Ilagan, Alexander Bukreyev, Christopher F. Basler, Terry L. Bowlin, Donald T. Moir, Daisy W. Leung, Gaya K. Amarasinghe

    Research output: Contribution to journalArticle

    8 Citations (Scopus)

    Abstract

    The 2014 Ebola outbreak in West Africa, the largest outbreak on record, highlighted the need for novel approaches to therapeutics targeting Ebola virus (EBOV). Within the EBOV replication complex, the interaction between polymerase cofactor, viral protein 35 (VP35), and nucleoprotein (NP) is critical for viral RNA synthesis. We recently identified a peptide at the N-terminus of VP35 (termed NPBP) that is sufficient for interaction with NP and suppresses EBOV replication, suggesting that the NPBP binding pocket can serve as a potential drug target. Here we describe the development and validation of a sensitive high-throughput screen (HTS) using a fluorescence polarization assay. Initial hits from this HTS include the FDA-approved compound tolcapone, whose potency against EBOV infection was validated in a nonfluorescent secondary assay. High conservation of the NP-VP35 interface among filoviruses suggests that this assay has the capacity to identify pan-filoviral inhibitors for development as antivirals.

    Original languageEnglish (US)
    Pages (from-to)190-198
    Number of pages9
    JournalACS Infectious Diseases
    Volume3
    Issue number3
    DOIs
    StatePublished - Mar 10 2017

    Fingerprint

    Ebolavirus
    Nucleoproteins
    Viral Proteins
    Virus Replication
    Disease Outbreaks
    Ebola Hemorrhagic Fever
    Nucleocapsid Proteins
    Fluorescence Polarization
    Western Africa
    Viral RNA
    Antiviral Agents
    Peptides
    Pharmaceutical Preparations
    In Vitro Techniques
    Therapeutics

    Keywords

    • Ebola virus
    • fluorescence polarization assay
    • high-throughput screening
    • nucleoprotein
    • VP35

    ASJC Scopus subject areas

    • Infectious Diseases

    Cite this

    A Sensitive in Vitro High-Throughput Screen to Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface. / Liu, Gai; Nash, Peter J.; Johnson, Britney; Pietzsch, Colette; Ilagan, Ma Xenia G.; Bukreyev, Alexander; Basler, Christopher F.; Bowlin, Terry L.; Moir, Donald T.; Leung, Daisy W.; Amarasinghe, Gaya K.

    In: ACS Infectious Diseases, Vol. 3, No. 3, 10.03.2017, p. 190-198.

    Research output: Contribution to journalArticle

    Liu, G, Nash, PJ, Johnson, B, Pietzsch, C, Ilagan, MXG, Bukreyev, A, Basler, CF, Bowlin, TL, Moir, DT, Leung, DW & Amarasinghe, GK 2017, 'A Sensitive in Vitro High-Throughput Screen to Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface', ACS Infectious Diseases, vol. 3, no. 3, pp. 190-198. https://doi.org/10.1021/acsinfecdis.6b00209
    Liu, Gai ; Nash, Peter J. ; Johnson, Britney ; Pietzsch, Colette ; Ilagan, Ma Xenia G. ; Bukreyev, Alexander ; Basler, Christopher F. ; Bowlin, Terry L. ; Moir, Donald T. ; Leung, Daisy W. ; Amarasinghe, Gaya K. / A Sensitive in Vitro High-Throughput Screen to Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface. In: ACS Infectious Diseases. 2017 ; Vol. 3, No. 3. pp. 190-198.
    @article{1b8a640b15bb48b594fea38b62b8e5d4,
    title = "A Sensitive in Vitro High-Throughput Screen to Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface",
    abstract = "The 2014 Ebola outbreak in West Africa, the largest outbreak on record, highlighted the need for novel approaches to therapeutics targeting Ebola virus (EBOV). Within the EBOV replication complex, the interaction between polymerase cofactor, viral protein 35 (VP35), and nucleoprotein (NP) is critical for viral RNA synthesis. We recently identified a peptide at the N-terminus of VP35 (termed NPBP) that is sufficient for interaction with NP and suppresses EBOV replication, suggesting that the NPBP binding pocket can serve as a potential drug target. Here we describe the development and validation of a sensitive high-throughput screen (HTS) using a fluorescence polarization assay. Initial hits from this HTS include the FDA-approved compound tolcapone, whose potency against EBOV infection was validated in a nonfluorescent secondary assay. High conservation of the NP-VP35 interface among filoviruses suggests that this assay has the capacity to identify pan-filoviral inhibitors for development as antivirals.",
    keywords = "Ebola virus, fluorescence polarization assay, high-throughput screening, nucleoprotein, VP35",
    author = "Gai Liu and Nash, {Peter J.} and Britney Johnson and Colette Pietzsch and Ilagan, {Ma Xenia G.} and Alexander Bukreyev and Basler, {Christopher F.} and Bowlin, {Terry L.} and Moir, {Donald T.} and Leung, {Daisy W.} and Amarasinghe, {Gaya K.}",
    year = "2017",
    month = "3",
    day = "10",
    doi = "10.1021/acsinfecdis.6b00209",
    language = "English (US)",
    volume = "3",
    pages = "190--198",
    journal = "ACS Infectious Diseases",
    issn = "2373-8227",
    publisher = "American Chemical Society",
    number = "3",

    }

    TY - JOUR

    T1 - A Sensitive in Vitro High-Throughput Screen to Identify Pan-filoviral Replication Inhibitors Targeting the VP35-NP Interface

    AU - Liu, Gai

    AU - Nash, Peter J.

    AU - Johnson, Britney

    AU - Pietzsch, Colette

    AU - Ilagan, Ma Xenia G.

    AU - Bukreyev, Alexander

    AU - Basler, Christopher F.

    AU - Bowlin, Terry L.

    AU - Moir, Donald T.

    AU - Leung, Daisy W.

    AU - Amarasinghe, Gaya K.

    PY - 2017/3/10

    Y1 - 2017/3/10

    N2 - The 2014 Ebola outbreak in West Africa, the largest outbreak on record, highlighted the need for novel approaches to therapeutics targeting Ebola virus (EBOV). Within the EBOV replication complex, the interaction between polymerase cofactor, viral protein 35 (VP35), and nucleoprotein (NP) is critical for viral RNA synthesis. We recently identified a peptide at the N-terminus of VP35 (termed NPBP) that is sufficient for interaction with NP and suppresses EBOV replication, suggesting that the NPBP binding pocket can serve as a potential drug target. Here we describe the development and validation of a sensitive high-throughput screen (HTS) using a fluorescence polarization assay. Initial hits from this HTS include the FDA-approved compound tolcapone, whose potency against EBOV infection was validated in a nonfluorescent secondary assay. High conservation of the NP-VP35 interface among filoviruses suggests that this assay has the capacity to identify pan-filoviral inhibitors for development as antivirals.

    AB - The 2014 Ebola outbreak in West Africa, the largest outbreak on record, highlighted the need for novel approaches to therapeutics targeting Ebola virus (EBOV). Within the EBOV replication complex, the interaction between polymerase cofactor, viral protein 35 (VP35), and nucleoprotein (NP) is critical for viral RNA synthesis. We recently identified a peptide at the N-terminus of VP35 (termed NPBP) that is sufficient for interaction with NP and suppresses EBOV replication, suggesting that the NPBP binding pocket can serve as a potential drug target. Here we describe the development and validation of a sensitive high-throughput screen (HTS) using a fluorescence polarization assay. Initial hits from this HTS include the FDA-approved compound tolcapone, whose potency against EBOV infection was validated in a nonfluorescent secondary assay. High conservation of the NP-VP35 interface among filoviruses suggests that this assay has the capacity to identify pan-filoviral inhibitors for development as antivirals.

    KW - Ebola virus

    KW - fluorescence polarization assay

    KW - high-throughput screening

    KW - nucleoprotein

    KW - VP35

    UR - http://www.scopus.com/inward/record.url?scp=85017521528&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85017521528&partnerID=8YFLogxK

    U2 - 10.1021/acsinfecdis.6b00209

    DO - 10.1021/acsinfecdis.6b00209

    M3 - Article

    VL - 3

    SP - 190

    EP - 198

    JO - ACS Infectious Diseases

    JF - ACS Infectious Diseases

    SN - 2373-8227

    IS - 3

    ER -